Ryan Sansom centers his practice on advising privately held and publicly traded emerging companies, with a strong emphasis on companies across the spectrum of the life sciences industry, including biotechnology, medical devices, healthcare IT and health and wellness. Ryan’s representation of life sciences and technology companies spans the entire emerging company life-cycle, including pre-incorporation planning, formation and founder matters, seed, venture capital and growth equity financings, public offerings and mergers and acquisitions, and other complex transactions. In addition, Ryan often represents venture capital firms in connection with their investments in emerging companies and underwriters in connection with public offerings by emerging companies.

Download full bio 


  • Adagio Therapeutics – $356 Million IPO 

  • Molecular Partners – $64 Million IPO 

  • Adagio Therapeutics Raises $336 Million Series C for COVID-19 Treatment and Prevention 

  • VectivBio – $147 Milion IPO 

  • Finch Therapeutics – $128 Million IPO 

  • View all


  • Boston University School of Law
    JD, cum laude, 2007

  • Westfield State College
    BA, summa cum laude, 2004

Admissions & Credentials